| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GALT | Stock Option (right to buy) | Award | $0 | +91,000 | $0.000000 | 91,000 | 23 Jan 2025 | Common Stock | 91,000 | $1.23 | Direct | F1, F2 | |
| transaction | GALT | Restricted Stock Unit | Award | $0 | +84,000 | $0.000000 | 84,000 | 23 Jan 2025 | Common Stock | 84,000 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. |
| F2 | The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026. |
| F3 | The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. |
| F4 | Restricted Stock Units vest upon the earlier of December 31, 2025 or signing a partnership agreement. |